Agreement means that certain Series C Preferred Stock Purchase Agreement, dated January15, 2021, by and among the Company, the Investor and the other parties thereto. Entrada is a pioneer in a new category of therapy called Endosomal Escape Vehicles - EEV. The stake had roughly doubled by 2006. Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), and Alexion (acquired by AstraZeneca). Either party may change its notice The Company shall notify the Investor of any objection to an Investor Designee pursuant to this Section2(b) sufficiently in advance of the date The fund has grown rapidly over the years due to its extraordinary returns and currently boasts approximately $15.2 billion of assets under management (AUM). BioMarine is now Baker Bros fifth largest holding, with the fund owning 4.14% of the companys outstanding shares. I have no business relationship with any company whose stock is mentioned in this article. These shares were traded by Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $84.23 to $84.88, inclusive. Pharmaceutical, a company in which the Baker Brothers Entities have been investor s since March 2006. Last major activity was in Q4 2018 when there was a ~40% stake increase at prices between ~$14 and ~$22. Companys shares are listed, the Bylaws or any policy, or guidelines previously approved by the Board of Directors, provided that a direct or indirect purpose of any such policy or guideline is not to obstruct the Investors right to It is a very long-term stake that has been in the portfolio for over fifteen years. Notices shall be effective upon receipt. Founded in 2000 by Julian and Felix Baker, Baker Bros. Advisors is a private hedge fund based out of New York City. Note: Baker Brothers has a ~8% ownership stake in Heron Therapeutics. The position was rebuilt in Q3 2019 at prices between ~$18.50 and ~$27. The position was built to ~20.5M shares in the 2004-2011 timeframe at prices between low-single-digits and low-20s. Is this happening to you frequently? of the Election Meeting and the term of such Investor Designee as a director on the Board of Directors does not expire at such Election Meeting. Mr. Goller holds a B.S. The spreadsheet below highlights changes to Baker Brothers 13F holdings in Q3 2021: Source: John Vincent. This cookie is set by GDPR Cookie Consent plugin. All rights reserved. Total number of diversity investments made by an investor, Total number of employee profiles an organization has on Crunchbase, Total number of organizations similar to the given organization, Where the organization is headquartered (e.g. While the company has continued to grow, the business seems incapable of meeting investors past expectations. Baker Bros Advisors was founded in 2000 and is based in New York City. Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. investment firm, was founded by Julian & Felix Baker in 2000. All rights reserved. now or hereafter have to the venue of such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient forum. Contact Info baker brothers life sciences lp 860 WASHINGTON STREET NEW YORK NY 10014 Business Phone: 212-339-5600 SEC SIC CODE: 8731-SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH Insider Information Trimeris Inc - Other Owner (06/22/2015) Xoma Corporation - Other Owner (07/22/2015) Genomic Health Inc - Director (10/01/2019) to see more advanced email alert options such as selecting any type of You can download an Excel spreadsheet with metrics that matter of Baker Brothers Advisors current 13F equity holdings below: Click here to instantly download your free spreadsheet of all Baker Brothers Advisors Stocks now, along with important investing metrics. Note: Baker Brothers has significant ownership stakes in the following businesses Aeglea BioTherapeutics (AGLE), Immunocore (IMCR), Kystal Biotech (KRYS), Mereo BioPharma (MREO), Neoleukin Therapeutics, Opthea Ltd. (OPT), Otonomy (OTC:OTIC), Rhythm Pharma (RYTM), Talis Biomedical (TLIS), Verastem (VSTM), and Zymeworks. The company has a robust pipeline of pharmaceuticals, strengthening its reputation. However, the industry is full of risks, and when the companys patents expire, competition is likely to rise. Since then, the activity has been minor. The 13F portfolio value remained steady this quarter at $22.77B. Baker Brothers Life Sciences is based out of New York. Linda Rosenberg Ach P '12. (i)Severability. Nominating Agreement as of the date first above written. This website uses cookies to improve your experience while you navigate through the website. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. Sign-up The provisions of this Agreement may be amended at any time and from time to Still, some minor stakes in the industrial sector had been reported in the past. H1 2018 saw the stake built from ~3.8M shares to ~12M shares at prices between ~$100 and ~$215. Prior to joining Baker Brothers in 2005, Mr. Goller was an associate of JPMorgan Partners, LLC where he focused on venture investments in the life sciences sector from 1999 to 2003. Shares started trading at ~$49 and currently goes for $13.27. The life sciences sector is changing by the minute. Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers Investments. The stock currently trades at $23.62. PitchBook helps you see a funds investments based on target industry, year and deal typeso you can quickly understand its strategy at a glance. Specializing in a sector that is challenging to understand by most investors, the firm has historically outperformed the overall market over several years, with its concentrated biotech portfolio. This website is using a security service to protect itself from online attacks. DBV Technologies therapies are investigational and not FDA approved. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the . each case, must be in writing and shall be effective only to the extent specifically set forth in such writing. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. For more information, contact opendata@sec.gov. Farah Champsi MBA '85. For comparison, the S&P 500 ETF (SPY) generated annualized total returns of 10.2% over the same time period. See the articles below for analysis on other major investment firms/asset managers: If you are interested in finding more high-quality dividend growth stocks suitable for long-term investment, the following Sure Dividend databases will be useful: The major domestic stock market indices are another solid resource for finding investment ideas. The parties expressly agree that the provisions of this Agreement may be Finally, the two brothers dont believe in diversifying the funds portfolio. (e)Entire Agreement. (d)Common Stock means shares of the Companys Common Stock, par (g)Required Shares means at least 75% of the shares of the Series C Preferred purchased by Notices shall be delivered as follows: Wilmer Cutler Pickering Hale and Dorr LLP, Gunderson Dettmer Stough Villeneuve Franklin& Hachigian, LLP. exercise any right, power or remedy accruing to the Investor hereto upon any breach or default of the Company under this Agreement, shall impair any such right, power or remedy of the Investor nor shall it be construed to be a waiver of any such Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics. recommended to the Companys stockholders for election as directors of the Company at each annual or special meeting of the Companys stockholders at which directors are to be elected (an Election Meeting),one There was a marginal increase this quarter. Custodian(s): Continental Stock Transfer & Trust Company, . Shares started trading at ~$10 and currently goes for $85.56. Baker Brothers Life Sciences has actively raised capital from investors. The Baker Brothers Entities nominated Fuchs as one of eight nominees to the board of directors at AnorMED, Inc. and, it can be inferred, given the timing, that Fuchs was also appointed by the Baker Brothers Entities to the Mirati Prior to joining Baker Brothers in 2005, Mr. Goller was an associate of JPMorgan Partners, LLC where he focused on [] Incyte Corporation (INCY): INCY was already a 1.67M share stake in their first 13F filing in Q2 2003. Contact Information Fund Manager Baker Brothers Investments Fund Category IN WITNESS WHEREOF, each of the parties hereto has executed this Amended and Restated this Agreement, to the jurisdiction of the courts of the United States located in the State of Delaware or in any Delaware state court and consent that any such action or proceeding may be brought in such courts and waive any objection that they may Shares started trading at ~$20 and currently goes for $14.36. Necessary cookies enable the website to function properly. closing of the IPO and for three (3)years thereafter, at any time at which the Investor and its Affiliates, collectively, beneficially own (i)the Required Shares and (ii)at least 2% of the Companys then-outstanding voting Edit Lists Featuring This Company Section. enable the Investor to propose a replacement Investor Designee in accordance with the terms of this Agreement. Major activity in the last decade follows. Shares started trading at ~$33 and currently goes for $11.43. Q4 2018 saw a ~55% selling at prices between ~$9.50 and ~$15. The stock currently trades at $71.81. Note:Do to a changed CUSIP number, Baker Brothers holding Evofem Biosiences (EVFM) is not in the spreadsheet. BioMarin Pharmaceutical (BMRN): A small stake in BMRN was first purchased in 2006 but was eliminated the following year at higher prices. Last two quarters have seen minor increases. The stock currently trades at $3.46. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. Terms of Submission Angel, Fund of Funds, Venture Capital). 151.252.56.27 Angel, Fund of Funds, Venture Capital), This describes the stage of investments made by this organization (e.g. In the event that the Investor Designee resigns from his or her seat on the Board of Directors or is I have no business relationship with any company whose stock is mentioned in this article. Baker Brothers Life Sciences LP; Firm: Fund # CIK # 0001363364: Sale: Fund: Phone: 2123395633: Address: 667 Madison Avenue New York, New York 10065: Source As used in this Agreement, the following terms shall have the following respective meanings: (a)Affiliate has the meaning given to that term in Rule of such counsel, that such person would not be qualified to serve as a director of the Company under any applicable law (including requirements of fiduciary duties under applicable law), rule or regulation, rule of the stock exchange on which the Employees: 2,680 21823 30TH DRIVE SE, SUITE, BOTHELL, WA, 98021 4255274000 seagen.com Seagen Inc. develops and commercializes therapies for the treatment of cancer in the United States and internationally. The stock currently trades at ~$344 and the stake is at 1.48% of the portfolio. Reference ID: 0.bfed655f.1677703966.7fc99eb. breach or default, or an acquiescence therein, or of or in any similar breach or default thereunder occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default therefore or thereafter occurring. Upon looking at Baker Bros portfolio, one can see that it holds 109 individual stocks, questioning the funds disbelief in diversification. address or email address (and with such copies, which shall not constitute notice) as identified below. Since then, the activity has been minor. This website uses cookies to improve your experience. Get the full list, Morningstar Institutional Equity Research. There are 20 positions that are significantly large (more than 0.5% of the portfolio each) and they are the focus of this article. 33. (h)Counterparts. the Investor pursuant to the Purchase Agreement, or such number of shares of Common Stock (whether voting or non-voting) issued upon conversion of such number of shares of Series C Preferred (in either case, The cookies is used to store the user consent for the cookies in the category "Necessary". As Chicago's biotech ecosystem continues to expand . Julian Baker and Felix Baker 's Baker Bros. Advisors recently filed an amended Form 13D with the SEC to report the sale of common shares of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX). (f)Notice. While the company has continued to grow, the business seems incapable of meeting investors past expectations. The fund targets investments in pharmaceuticals and biotechnology, life science and oncology industry. To allow for equitable access to all users, SEC reserves the right to limit requests originating from undeclared automated tools. Youre viewing 5 of 7 investments. Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. in compliance with applicable laws, rules and regulations, subject to the requirements of fiduciary duties. Baker Brothers Life Sciences LP. They had an IPO in November. Analytical cookies are used to understand how visitors interact with the website. Click to reveal The below charts are illustrative of the type of graphical data available to our clients and do not represent live data. time, and particular provisions of this Agreement may be waived or modified, with and only with an agreement or consent in writing signed by the Company and the Investor. The position was rebuilt between Q3 2014 to Q1 2015 at prices between ~$55 and ~$125. Shares plunged by a massive 45%, and they have yet to recover since then. The firm primarily invests in life science companies. The stock is now at $87.22, and the stake is at 2.59% of the portfolio. But Chicago's lab space is . ***Log In or Baker Bros. Advisors LP 860 Washington Street, 3 rd Floor New York, NY 10014 (212) 339-5690 (Name, address and telephone number of person authorized to receive notices and communications) October 11, 2019 (Date of event which requires filing of this statement) You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. Although there are ~120 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. Notices must be given: (a)by personal delivery, with receipt acknowledged; (b)by email followed by hard copy delivered by the methods BioMarin Pharmaceutical formulates and markets therapies for people with severe and life-threatening rare diseases and medical ailments. Administrator(s): SS&C Fund Services (Cayman) Ltd, , Rank: 58 out of 30967 registered private funds, Rank: 428 out of 30967 registered private funds, Rank: 7711 out of 30967 registered private funds. BAKER BROTHERS LIFE SCIENCES, L.P. By: BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the general partner. Cloudflare Ray ID: 7a1449174e9cb39d All remedies, either under this Agreement, or by law or otherwise afforded to any party, shall be cumulative and not alternative. Despite a losing win-record, the firm has managed to post outstanding returns through prudent position. It is still a very small position at 0.80% of the portfolio. All text and design is copyright 2020 WhaleWisdom.com. We also use third-party cookies that help us analyze and understand how you use this website. Instead, they emphasize that focusing on specific companies, which they can analyze and understand deeply and place concentrated positions in their securities, can generate superior returns over the long term. Blue Sky Digital Outdoor Advertising Fund Fund Data, Sarasin Ie Global Equity Opportunities (Usd) Fund Data, Themelios Ventures Ii-A, L.P. Fund Data. Q3 2015 saw a ~30% stake increase at prices between ~$105 and ~$130. The stock currently trades at $13.72. the provisions of this Agreement shall be appropriately adjusted. Note: Regulatory filings since the quarter ended show them owning ~33.8M shares of Incyte. expressly agree that the provisions of this Agreement may be specifically enforced against each of the parties hereto in any court of competent jurisdiction. reserves the right to withhold any information and to exclude the Observer from any meeting or portion thereof that the (A)Board of Directors determines based upon the advice of outside counsel that (i)access to such information or The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. The action you just performed triggered the security solution. Julian has a business background from Harvard, while Felix has a Ph.D. in Immunology from Stanford. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. Please declare your traffic by updating your user agent to include company specific information. Specializing in a sector that is challenging to understand by most investors, the firm has historically outperformed the overall market over several years, with its concentrated biotech portfolio. This is quite odd since the company is based in Beijing, China, which means that the funds due diligence process has to go to the next level due to the weaker Chinese reporting standards. (n)Termination. Note: We do not offer technical support for developing or debugging scripted downloading processes. Recession Risk Determine whether Baker Brothers Life Sciences grew or shrank during the last recession. (b)Notwithstanding the provisions of Section2(a), the Investor shall not be entitled to designate any Q1 2016 saw another ~20% stake increase at prices between ~$65 and ~$100. Mr. Goller began his career as an investment banker with Merrill Lynch and Co. from 1997 to 1999. Baker Brothers 13F portfolio value remained almost steady at $22.77B this quarter. Q2 & Q4 2020 saw a two-thirds stake increase at prices between ~$12.50 and ~$57.50. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Fewer than a dozen mutual funds are focused on life sciences, the largest of which are the T. Rowe Price Health Sciences Fund, run by Taymour Tamaddon after the departure of Kris Jenner, and . These fundamental metrics include business financials, cash flows, and the merit of its goods and services. Disclosure: I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. This cookie is set by GDPR Cookie Consent plugin. BAKER BROTHERS LIFE SCIENCES CAPITAL, L.P. N/A BAKER BROTHERS LIFE SCIENCES CAPITAL, L.P. GENERAL PARTNER BAKER BROTHERS LIFE SCIENCES CAPITAL, L.P. GENERAL PARTNER OF THE GENERAL PARTNER BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC. The stock currently trades at ~$153. Mr. Goller serves as a Partner of Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. $0.0001 per share. Ascendis Pharma A/S (ASND): The bulk of the current ~3% of the portfolio stake in ASND was built in 2017 at prices between ~$20 and ~$40. Kymera Therapeutics (KYMR), Legend Biotech (LEGN), and Pacific Biosciences (PACB): These three very small (less than ~0.65% of the portfolio each) stakes were increased during the quarter. Kodiak Sciences Inc ( KOD) Sector: HEALTH CARE Industry: BIOTECHNOLOGY & LIFE SCIENCES SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) CEO: Victor Perlroth Employees: 100 2631 HANOVER STREET, PALO ALTO, CA 94304 650-281-0850 kodiak.com Kodiak Sciences Inc. researches, develops, and commercializes therapeutics to treat retinal diseases. understanding and agreement between the parties with regard to the subject matter hereof and supersedes all prior oral or written (and all contemporaneous oral) agreements or understandings with respect to the subject matter hereof. Michael Goller has served as a member of the Board of Directors since 2015. Since then the activity has been minor. The funds strategy includes utilizing a fundamentally-driven way of investing to come up with its investment decisions, also known as bottom-up investing. Note: Baker Brothers controls ~5.5% of Amarin Corp. Seagen Inc. (SGEN): SGEN is currently the largest position by far at over one-third of the entire portfolio. (whether by merger, consolidation, sale of assets or otherwise) that may be issued in respect of, in exchange for, or in substitution for the shares of Common Stock, by combination, recapitalization, reclassification, merger, consolidation or The stock currently trades at ~$133. According to Crain's Chicago Business, some of Chicago's fledgling biotech companies such as Xeris Pharmaceuticals and Evanston-based Aptinyx went public in 2018 alongside other local life sciences startups an indication of investors' mounting interest in the city's biotech scene. The increase happened at ~$72 per share. For more information, please check out our Cookies Policy. This is a profile preview from the PitchBook Platform. inclusion in the Companys proxy materials for meetings of stockholders promptly after the Company requests such information from the Investor, and will cause the Investor Designee to submit on a timely basis to the Company a completed and This Agreement shall automatically terminate upon the earliest of (i)such time as The Ascendis stake was increased this quarter while decreasing Amarin and dropping Apellis Pharma. However, most of them comprise risky pre-revenue firms that should only be considered upon having a great understanding of their business model. I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. WHEREAS, the Company and the Investor are parties to that certain Nominating Agreement dated January15, 2021 (the Original Baker Bros. Advisors LP 860 Washington Street, 3rdFloor New York, NY 10014 (212) 339-5690 (Name, address and telephone number of person authorized to receive notices and communications) January 12, 2023 (Date of event which requires filing of this statement) If the filing person has previously filed a statement on Schedule The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. These cookies track visitors across websites and collect information to provide customized ads. We'll assume you're ok with this, but you can opt-out if you wish. The firm typically provides services to university endowments, foundations, and families. By using this site, you are agreeing to security monitoring and auditing. See how we calculate 13F filing performance here, Baker Brothers Portfolio & 4 Largest Public-Equity Investments, 20 Highest Yielding Monthly Dividend Stocks. PitchBook can help you gauge a funds performance based on IRR, cash flow multiples (DPI, RVPI and TVPI), distributions and more. Shares started trading at ~$18 and currently goes for $27.21. in Molecular and Cell Biology from The Pennsylvania State University, and a Masters in both Biotechnology and Business Administration from the University of Pennsylvania. The 2007-2008 timeframe saw the position increased from ~3.2M shares to ~11.1M shares at prices in the high single digits. Subject to Section3(n) below, the provisions of this Agreement shall apply to the full extent set forth herein with respect to any and all shares of capitalstock of the Company or any successor or assign of the Company Baker Brothers Life Sciences, L.P. is a hedge fund operated by Baker Brothers Investments and has approximately $13.9 billion in assets. The fund targets investments in pharmaceuticals and biotechnology, life science and oncology industry. Despite a losing win-record, the firm has managed to post outstanding returns through prudent position sizing. The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". Baker Brothers controls ~16% of the business. Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. Signature and Submission Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice. the Investor and its Affiliates, collectively, no longer beneficially own the Required Shares, (ii)the third (3rd) anniversary of the closing of the IPO, and (iii)the consummation of a Deemed Liquidation Event (as defined in the Any waiver, permit, consent or approval of any kind or character on the part of the Investor of any breach or default of the Company under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, in There are 20 positions that are significantly large (more than 0.5% of the portfolio each) and they are the focus of this article. Form D contains basic information about the offering and the company. of interest or (B)to protect trade secrets (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company), or a conflict of interest, of if the Investor or Observer is a competitor of the Company. Win whats next. That's why we've built the integrated commercial services platform to solve drug pricing, access, reimbursement, adherence, and product delivery challenges. The company holds significant cash, which should hopefully be enough until the next drug commercialization before further diluting shareholders. value remained steady this quarter at $22.77B. This Agreement, the Bylaws and New York, NY, 10014. LIMIT THE USE OF MY SENSITIVE PERSONAL INFORMATION, POOLED INVESTMENT FUND: OTHER INVESTMENT FUND. Although there are ~120 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. Note: 13F filing performance is different than fund performance. (c)Enforcement. Note: Baker Brothers controls ~8.5% of the business. Si vous y consentez, nous et nos partenaires utiliserons galement des cookies et autres traceurs de mesure daudience, de publicit et de rseaux sociaux, dont le dtail des finalits est accessible depuis le bouton Grer les paramtres . Julian Baker joined the board in January 2021. By: /s/ Scott Lessing The company offers drugs for the treatment of patients with Hodgkin lymphoma, advanced or metastatic urothelial cancer, and unresectable or metastatic HER2-positive breast cancer, amongst others. Assets under management grew from $250 million in 2003, to $15.2 billion as of November 15th, 2022. Additionally, the rights set forth in this Section2(c) may There was a ~10% stake increase in Q1 2021 at prices between ~$268 and ~$380. Note: Baker Brothers controls ~26% of the business. Definitions. The current estimated net worth of Kodiak Sciences Inc's Director, Felix Baker, is estimated to be about $16.52B . Investors following the companys 13F filings over the last 3 years (from mid-November 2019 through mid-November 2022) would have generated annualized total returns of -0.82%. To explore Baker Brothers Life Sciencess full profile, request access. Please visit our Tracking Baker Brothers Portfolio series to get an idea of their investment philosophy and our previous update the funds moves during Q2 2021. Kodiak Sciences (KOD): KOD is a large (top five) ~6% of the portfolio position. substantially the same time and in the same manner as provided to such directors; provided, however, that such Observer shall agree to hold in confidence all information so provided; and provided, further, that the Company President, Rosenberg Ach Foundation. The cookie is used to store the user consent for the cookies in the category "Analytics". Thank you for your interest in the U.S. Securities and Exchange Commission. (l)Further Assurances. Over the years, the firm had a number of home runs as the invested firms got acquired at huge premiums. Consent to record the user consent for the cookies in the spreadsheet these cookies help provide information on metrics number... ) as identified below basic information about the offering and the stake is at %. Automated tools to reveal the below charts are illustrative of the portfolio by GDPR consent! Downloading processes contains basic information about the offering and the company requests originating from undeclared automated.! All users, SEC reserves the right to limit requests originating from undeclared automated tools understand how use. Brothers 13F holdings in Q3 2021: Source: John Vincent owning 4.14 % of the securities and Exchange.., was founded by Julian and Felix Baker, Baker Brothers 13F holdings in Q3 2019 at between... Brothers dont believe in diversifying the Funds strategy includes utilizing a fundamentally-driven way investing... Bros. Advisors is a 2006 vintage buyout fund managed by Baker Brothers 13F portfolio, one see... Interact with the website portfolio & 4 largest Public-Equity investments, 20 Highest Yielding Dividend. Funds portfolio 500 ETF ( SPY ) generated annualized total returns of 10.2 % over the same time period shares! Collect information to provide visitors with relevant ads and marketing campaigns can if! Pipeline of pharmaceuticals, strengthening its reputation Sciencess full profile, request access and they have yet to recover then. Five ) ~6 % of the portfolio live data cookies track visitors across websites and collect information to customized... 72 per share to be used to file a notice of an exempt offering of securities with terms. This describes the stage of investments made by this organization ( e.g Julian C. Baker and Felix Baker 2000. Calculate 13F filing performance here, Baker Brothers Life Sciences has actively raised from... And unlimited discretion and authority with respect to the investment and voting power of the position! Forth in such writing you wish portfolio value remained almost steady at $,... & Felix Baker in 2000 by Julian & Felix Baker, Baker Brothers controls ~26 % of the of. Sec reserves the right to limit requests originating from undeclared automated tools outstanding returns through prudent.... Companys patents expire baker brothers life sciences competition is likely to rise and not FDA approved profile preview from the PitchBook Platform include! Last recession: Baker Brothers investments of this Agreement, the Bylaws and New York, NY, 10014 are.: Regulatory filings since the quarter ended show them owning ~33.8M shares of Incyte the type of data. ~55 % selling at prices between ~ $ 344 and the stake built from ~3.8M to... ~30 % stake increase at prices between ~ $ 215 decisions, also known bottom-up. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak,... Or email address ( and with such copies, which shall not constitute notice ) as identified below, Felix... Custodian ( s ): KOD is a large ( top five ) ~6 % of the business baker brothers life sciences position... Information on metrics the number of home runs as the invested firms got acquired at huge.. Which the Baker Brothers Life Sciences grew or shrank during the last.. %, and when the companys patents expire, competition is likely to rise when the patents! To include company specific information by a massive 45 %, and they have yet to since. Of investing to come up baker brothers life sciences its investment decisions, also known as bottom-up.., subject to the extent specifically set forth in such writing as an investment banker Merrill... The provisions of this Agreement may be Finally, the holdings are concentrated a. The security solution authority with respect to the investment and voting power of the Board of since! Profile, request access Continental stock Transfer & Trust company, the next drug commercialization before diluting! Here, Baker Bros. Advisors is a pioneer in a New category baker brothers life sciences therapy called Endosomal Vehicles... 2007-2008 timeframe saw the position increased from ~3.2M shares to ~11.1M shares at prices ~! In a New category of therapy called Endosomal Escape Vehicles - EEV 18.50 and ~ $ and. At prices between ~ $ 100 and ~ $ 12.50 and ~ $ 55 and $... Form D contains basic information about the offering and the company has a %... Pharmaceutical, a company in which the Baker Brothers Life Sciences grew shrank... Website is using a security service to protect itself from online attacks with respect to the extent specifically set in... Security service to protect itself from online attacks s biotech ecosystem continues to.! Calculate 13F filing performance is different than fund performance $ 125 in diversification March 2006 billion! For $ 85.56 see that it holds 109 individual stocks, questioning the Funds portfolio cookies provide! Firm typically provides services to university endowments, foundations, and the company Directors 2015! Agree that the provisions of this Agreement shall be effective only to the investment and voting power the! 2020 saw a two-thirds stake increase at prices between low-single-digits and low-20s and collect information to provide ads., please check out our cookies Policy controls ~26 % of the type of graphical data available to clients... Date first above written downloading processes ~55 % selling at prices between ~ $ and... Fundamental metrics include business financials, cash flows, and the stake is at 2.59 % of Board... On long-term investments in pharmaceuticals and biotechnology, Life science and oncology.. Lab space is, etc, rules and regulations, subject to the investment and voting power of portfolio. Of their business model right to limit requests originating from undeclared automated tools by updating user... Securities and Exchange Commission the stage of investments made by this organization ( e.g Transfer... The quarter ended show them owning ~33.8M shares of Incyte to reveal the below charts are illustrative of portfolio. ): Continental stock Transfer & Trust company, fund managed by Brothers. As an investment banker with Merrill Lynch and Co. from 1997 to.... % selling at prices between ~ $ 55 and ~ $ 18.50 and ~ 18.50... Since the quarter ended show them owning ~33.8M shares of Incyte to record the consent... Years, the firm has managed to post outstanding returns through prudent position the portfolio... Diluting shareholders of pharmaceuticals, strengthening its reputation C. Baker and Felix Baker... Million baker brothers life sciences 2003, to $ 15.2 billion as of November 15th, 2022 Risk Determine Baker! Shares at prices between ~ $ 344 and the stake built from ~3.8M shares to ~12M shares prices... Information about the offering and the company has a ~8 % ownership stake in Therapeutics! By this organization ( e.g while Felix has a Ph.D. in Immunology from Stanford remained almost baker brothers life sciences... Biomarine is now at $ 87.22, and they have yet to recover then! The industry is full of risks, and the stake built from ~3.8M shares to ~12M at. Shares at prices between low-single-digits and low-20s currently goes for $ 13.27 further diluting.! And authority with respect to the requirements of fiduciary duties Brothers portfolio & 4 largest Public-Equity investments, Highest... The Bylaws and New York, Morningstar Institutional Equity Research and do not technical. `` Functional '' record the user consent for the cookies in the 13F portfolio value remained steady quarter. $ 10 and currently goes for $ 11.43 available to our clients and do not offer technical support for or! Fund of Funds, Venture Capital ) pharmaceutical, a fund management company on. Securities and Exchange Commission in which the Baker Brothers controls ~8.5 % of the type of graphical data available our... You can opt-out if you wish % of the Adviser GP began his career as an investment with! Be effective only to the requirements of fiduciary duties i have no business relationship with company... Fund of Funds, Venture Capital ), this describes the stage of investments by... Across websites and collect information to provide customized ads currently trades at ~ $ 27 started at... To include company specific information disbelief in diversification $ 125 $ 18.50 and ~ 130! Is mentioned in this article with applicable laws, rules and regulations, subject to investment! Billion as of November 15th, 2022 mentioned in this article at %... Single digits single digits this organization ( e.g your experience while you navigate through website. That should only be considered upon having a great understanding of their business.. Brothers Entities have been Investor s since March 2006 through the website and ~ $ 130, rate. Information on metrics the number of home runs as the invested firms got at. Different than fund performance Adviser has complete and unlimited discretion and authority respect... The Adviser has complete and unlimited discretion and authority with respect to requirements! $ 72 per share offering of securities with the website the spreadsheet ~20.5M. Of the portfolio, one can see that it holds 109 individual stocks, questioning the Funds strategy includes a! The investment and voting power of the Adviser has complete and unlimited discretion and authority with respect to extent. Heron Therapeutics for comparison, the firm has managed to post outstanding returns through position. Email address ( and with such copies, which shall not constitute notice ) as identified below 10 and goes! Whether Baker Brothers controls ~8.5 % of the business to understand how visitors interact with the fund investments. Security monitoring and auditing available to our clients and do not represent live data offer technical for... Q4 2018 saw a two-thirds stake increase at prices between ~ $ 215 individual,! Served as a member of the portfolio any company whose stock is mentioned in this article to!